Lilly’s $2.75 B Bet on AI Drug Discovery: A Potential Turning Point for Pharma R&D

Lilly’s recent RMB 2.75 billion investment in AI-driven drug discovery firm Insilico Medicine signals a strategic shift from using AI as a supplementary tool to a core engine, highlighting both the promise of accelerated target identification and the lingering challenges of clinical validation, data quality, and regulatory acceptance.

AI drug discoveryInsilico MedicineLilly investment

0 likes · 5 min read

Lilly’s $2.75 B Bet on AI Drug Discovery: A Potential Turning Point for Pharma R&D

DevOps

Feb 8, 2021 · R&D Management

Principles and Practices of the Five Dimensions of R&D Organizational Transformation

This article outlines the five key dimensions—organizational structure, agile process, culture, team capability, and technology—of R&D transformation, explaining their principles, common challenges, and practical practices for building high‑efficiency development teams in the financial industry.

R&D transformationTechnical transformationteam capability

0 likes · 18 min read

Principles and Practices of the Five Dimensions of R&D Organizational Transformation

DevOps

Feb 2, 2021 · R&D Management

Key Factors and Methods for Transforming R&D Organizations

The article outlines a systematic approach to R&D organization transformation, emphasizing leadership support, team motivation, clear mission‑vision‑strategy goals, measurable roadmaps, and iterative execution across five dimensions to boost efficiency and agility in the digital era.

Goal SettingR&D transformationRoadmap

0 likes · 13 min read

Key Factors and Methods for Transforming R&D Organizations

Lilly’s $2.75 B Bet on AI Drug Discovery: A Potential Turning Point for Pharma R&D

Principles and Practices of the Five Dimensions of R&D Organizational Transformation

Key Factors and Methods for Transforming R&D Organizations

Lilly’s $2.75 B Bet on AI Drug Discovery: A Potential Turning Point for Pharma R&D